Implantable scaffolds and methods for treatment of sinusitis

• US 10,278,812 B2
• Filed: 09/11/2017
• Issued: 05/07/2019
• Est. Priority Date: 06/29/2015
• Status: Active Grant

• Current Assignee: Lyra Therapeutics, Inc.
• Original Assignee: 480 Biomedical, Inc.
• Inventors: You, Changcheng, Pham, Quynh, Concagh, Danny, Zugates, Gregory
• Primary Examiner(s): Prebilic, Paul B
• Application Number:
  US15/700,478
• Publication Number:
  US 20170367819A1
• Time in Patent Office: 603 Days
• CPC Class Codes: A61F 2/18 Internal ear or nose parts, e.g. ear-drums implants for middle ear ventilation or drainage A61F11/202
• CPC Class Codes: A61F 2/186 Nose parts
• CPC Class Codes: A61F 2/90 characterised by a net-like or mesh-like structure
• CPC Class Codes: A61F 2210/0004 bioabsorbable
• CPC Class Codes: A61F 2250/0031 made from both resorbable and non-resorbable prosthetic parts, e.g. adjacent parts
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61K 31/58 containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin digitoxin A61K31/7048
• CPC Class Codes: A61L 2300/222 Steroids, e.g. corticosteroids
• CPC Class Codes: A61L 2300/41 Anti-inflammatory agents, e.g. NSAIDs
• CPC Class Codes: A61L 2300/604 Biodegradation
• CPC Class Codes: A61L 2300/608 having two or more layers
• CPC Class Codes: A61L 2420/08 Coatings comprising two or more layers
• CPC Class Codes: A61L 27/18 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• CPC Class Codes: A61L 27/26 Mixtures of macromolecular compounds
• CPC Class Codes: A61L 27/34 Macromolecular materials
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 27/56 Porous materials, e.g. foams or sponges
• CPC Class Codes: A61L 31/06 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds A61L31/041 takes precedence
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: C08L 67/02 : Polyesters derived from dicarboxylic acids and dihydroxy compounds C08L67/06 takes precedence
• CPC Class Codes: C08L 67/04 : Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence

Abstract

This disclosure describes, inter alia, materials, devices, kits and methods for the treatment of chronic sinusitis. Disclosed are medical scaffolds configured for placement within a sinus of a patient, methods of making the implants and methods of treatment. The scaffolds comprise a woven or non-woven structure having a substantially tubular configuration, a conformal coating over the tubular scaffold and optionally, a drug coating.

Claims

1. A scaffold configured for implantation into a human sinus comprising:

(a) a tubular scaffold comprising a plurality of braided polymeric strands that comprise a first biodegradable polymer material and

(b) a conformal coating over the tubular scaffold that comprises a crosslinked biodegradable elastomer material, wherein the biodegradable elastomer material is formed by reacting a branched poly(lactide-co-caprolactone) polyol with a diisocyanate crosslinking agent; and

wherein the scaffold is adapted to conform to the shape of the sinus cavity.

2. The scaffold of claim 1, wherein the first biodegradable polymer material comprises poly(lactide-co-glycolide).

3. The scaffold of claim 1, wherein the scaffold comprises between 8 and 64 polymeric strands.

4. The scaffold of claim 1, wherein the braided polymeric strands cross each other at a braid angle ranging from 80°

to 140°

.

5. The scaffold of claim 1, wherein the poly(lactide-co-caprolactone) is hydroxyl-terminated.

6. The scaffold of claim 1, wherein the biodegradable elastomer material comprises poly(lactide-co-caprolactone) having molar percentage of lactide ranging from 30 to 50% and a molar percentage of caprolactone ranging from 50 to 70%.

7. The scaffold of claim 5, wherein the biodegradable elastomer material further comprises urethane and/or urea crosslinks.

8. The scaffold of claim 1, wherein the branched poly(lactide-co-caprolactone) polyol is reacted with the diisocyanate crosslinking agent in the presence of a 1-substituted C8-C18 alcohol.

9. The scaffold of claim 1, further comprising a therapeutic-agent-containing layer comprising a therapeutic agent and a second biodegradable polymer material which may be the same as or different from the first biodegradable polymer material.

10. The scaffold of claim 9, wherein the second biodegradable polymer material comprises poly(lactide-co-caprolactone).

11. The scaffold of claim 10, wherein the second biodegradable polymer material comprises poly(lactide-co-caprolactone) having molar percentage of lactide ranging from 70 to 95% and a molar percentage of caprolactone ranging from 5 to 30%.

12. The scaffold of claim 10, wherein the therapeutic agent is a steroid.

13. The scaffold of claim 12, wherein the steroid is mometasone furoate.

14. The scaffold of claim 9, further comprising a topcoat layer comprising a third biodegradable polymer material disposed over the therapeutic-agent-containing layer, wherein the third biodegradable polymer material may be the same as or different from the first biodegradable polymer material and wherein the third biodegradable polymer material may be the same as or different from the second biodegradable polymer material.

15. The scaffold of claim 1, wherein the scaffold has an unconstrained diameter selected from the group consisting of (a) an unconstrained diameter ranging from 6 to 10 mm, (b) an unconstrained diameter ranging from 10 to 15 mm, (c) an unconstrained diameter ranging from 15 to 20 mm, and (d) an unconstrained diameter ranging from 20 to 60 mm.

16. The scaffold of claim 1, wherein after holding the tubular scaffold in a 34°

C., 80% relative humidity environment for 10 weeks in a compressed state between two parallel flat plates such that the axis of the tubular scaffold is parallel to the parallel flat plates and such that the tubular scaffold is compressed between the parallel flat plates to a point where a first distance between the parallel flat plates is 17% of the initial unconstrained diameter such that the tubular scaffold has a first minimum width measured perpendicular to the axis that is equal to the first distance, and wherein after removal the tubular scaffold from the compressed state for six hours, the minimum width of the tubular scaffold recovers to a second minimum width measured perpendicular to the axis that is at least 250% of the first minimum width.

17. The scaffold of claim 1, wherein after holding the tubular scaffold in a 34°

C., 80% relative humidity environment for 10 weeks in a compressed state between two parallel flat plates such that the axis of the tubular scaffold is parallel to the parallel flat plates and such that the tubular scaffold is compressed between the parallel flat plates to a point where a first distance between the parallel flat plates is 8.5% of the initial unconstrained diameter such that the tubular scaffold has a first minimum width measured perpendicular to the axis that is equal to the first distance, and wherein after removal the tubular scaffold from the compressed state for six hours, the minimum width of the tubular scaffold recovers to a second minimum width measured perpendicular to the axis that is at least 450% of the first minimum width.

18. A scaffold of claim 1, wherein said scaffold is crimped and held at a diameter smaller than an as-manufactured diameter of the scaffold.

19. A method of treatment, wherein a scaffold in accordance with claim 1 is delivered to a human sinus.

20. The method of claim 19, wherein the scaffold is delivered to an ethomoid sinus of a human patient and wherein the scaffold has an unconstrained diameter ranging from 15 mm to 20 mm.

21. The method of claim 20, wherein the sinus is an ethomoid sinus that has been modified by functional endoscopic sinus surgery (FESS).

22. The method of claim 19, wherein the scaffold is delivered to a frontal sinus ostium, a maxillary sinus ostium or a sphenoid sinus ostium of a human patient and wherein the scaffold has an unconstrained diameter ranging from 6 mm to 10 mm.

23. The method of claim 22, wherein the sinus has been modified by functional endoscopic sinus surgery (FESS).

24. The method of claim 19, wherein the scaffold is delivered to a middle meatus sinus space of a human patient and wherein the scaffold has an unconstrained diameter ranging from 10 mm to 15 mm.